Global Sepsis Diagnostics Market Report and Forecast 2024-2032

Global Sepsis Diagnostics Market Outlook

The global sepsis diagnostics market size was valued at USD 725.6 million in 2023, driven by the rising merger and acquisitions amongst companies to offer early diagnosis of the condition. The market is expected to grow at a CAGR of 9.1% during the forecast period of 2024-2032, with the values likely to rise from USD 791.6 million in 2024 to USD 1587.4 million by 2032.

Sepsis Diagnostics: Introduction

Sepsis is a condition characterized by the body’s abnormal response to an infection. Common symptoms may include sweating, shivering, change in mental status, and shallow breathing, among others. The condition can be diagnosed via blood tests, which help in detecting evidence of infection, abnormal liver or kidney function, electrolyte imbalances or blood clotting issues. The imaging tests may include x-ray, ultrasound, CT scans, and MRIs.

Global Sepsis Diagnostics Market Analysis

Sepsis is one of the leading causes of deaths in the world. As per studies, early diagnosis can significantly help lower the fatalities associated with the condition. Therefore, there has been rising demand for sepsis diagnostics.

The sepsis diagnostics market growth is driven by the rising merger and acquisitions amongst companies to offer early diagnosis of the condition. In September 2023, Acutelines, a data-biobank and Inflammatix, a molecular diagnostics company announced their strategic partnership to develop a smart tool that helps in the recognition of sepsis while supporting clinical decisions in the early stages of the disease. This can mark as a crucial step since early recognition can be quite difficult in this condition.

With deeper understanding of human physiology and improved biotechnology techniques, the market for sepsis diagnostics has been experiencing major advancements. For instance, In November 2023, Abionic, along with their biomedical technology partner Lascco, entered a licensing agreement with Fapon, to utilize the pancreatic stone protein (PSP) biomarker for sepsis diagnosis.

SeptiCyte® RAPID by Immunexpress is another molecular test for sepsis diagnosis that employs the RT-PCR test to quantify the level of host response genes. It is intended for in-vitro diagnostic use and runs on the Biocartis Idylla™ Platform. Emerging technologies like these will certainly benefit the sepsis diagnostics market value in the forecast period.

Global Sepsis Diagnostics Market Segmentation

Market Breakup by Product Type

• Instruments

• Blood Culture Media

• Assay Kits and Reagents

• Software

Market Breakup by Technology

• Microbiology

• Molecular Diagnostics
  • Polymerase Chain Reaction (PCR)
  • DNA Microarrays
  • Syndromic Panel Testing
  • Others

• Immunoassays

• Flow Cytometry

• Others

Market Breakup by Pathogen

• Bacterial Sepsis
  • Gram-positive Bacteria
  • Gram-negative Bacteria

• Fungal Sepsis

• Viral Sepsis

• Others

Market Breakup by Type

• Laboratory Testing

• POC Testing

Market Breakup by Methods

• Automated Diagnostics

• Conventional Diagnostics

Market Breakup by End User

• Hospitals and Clinics

• Pathology and Reference Laboratories

• Research Institutes

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Sepsis Diagnostics Market Overview

The United States holds a substantial part of the sepsis diagnostics market share owing to a robust healthcare infrastructure. Increasing effort of the government and private institutions to offer awareness about the condition also plays a vital role for market growth. In July 2023, the Society of Critical Care Medicine (SCCM) received a grant from the Council of Medical Specialty Societies to enhance diagnostic excellence. The diagnostic program by SCCM focuses on providing knowledge and technology for precise diagnosis with the help of podcasts, toolkits, and webcasts.

The Asia Pacific region is projected to witness further growth with the increasing sepsis diagnostics market demand in the region. With increasing mergers and collaborations, the government has also been working on improving the medical infrastructure with a vision to integrate all digital and artificial intelligence-based tools into the system. A large population base spanning from the old as well as young generations is another essential factor for increased market demand.

Global Sepsis Diagnostics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• BioMérieux SA

• Becton, Dickinson and Company

• Thermo Fisher Scientific, Inc.

• F. Hoffmann-La Roche AG

• Danaher Corporation

• Luminex Corp.

• Bruker Corp.

• Cepheid

• Bruker Corporation

• Immunexpress, Inc. 

• Nanosphere, Inc.

• Seegene Inc.

• Response Biomedical Corp.

• Quidel Corporation

• Koninklijke Philips N.V.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report